Judy Chou, Ph.D., appointed to Governing Board of California’s Stem Cell & Gene Therapy Agency
Judy Chou, Ph.D. has been appointed to the Independent Citizens’ Oversight Committee (ICOC), the governing Board of the California Institute for Regenerative Medicine (CIRM).
Dr. Chou is the President, CEO and a member of the Board of Directors of AltruBio, a clinical stage biotech company that is focused on developing novel antibody therapeutics for the treatment of immune inflammatory diseases.
Dr. Chou has more than 20 years experience in drug development and biomanufacturing. Before joining AltruBio she headed the global Biotech organization at Bayer Pharmaceuticals. At Bayer she oversaw the development, manufacturing and distribution of the company’s more than $3bn product portfolio. She also oversaw more than 2,000 employees and led the drug development and launch activities for the biologics pipeline. In addition, she also served as the site head for Bayer’s facility in Berkeley, California, the company’s largest manufacturing site in the US.
Dr. Chou also has had leadership roles at Pfizer, Medivation Inc., Genentech and Wyeth Biopharma. She has won several awards and in 2018 was the recipient of the Most Influential Women in Business award by the San Francisco Business Times. She is currently an advisor at the UC Berkeley Engineering School and is working to promote diversity and inclusion through her advisory board position at Silicon Valley Women in Engineering.
Dr. Chou obtained her Ph.D., at Yale, her post-doctoral training at the Max-Planck Institute in Germany and was a research faculty member at Harvard University Medical School focusing on cell biology and neuroscience.
CIRM partners with both academia and industry in a ‘hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies’, with $5.5bn in funding and more than 150 active stem cell programs in its portfolio.
Dr. Chou was appointed to the CIRM Board by State Treasurer Fiona Ma, as the Executive Officer of a Commercial Life Science entity. She replaces Dave Martin.
